CHMP backing for cabozantinib augurs pivotal 2014 for Exelixis
This article was originally published in Scrip
Executive Summary
Plans to build a global oncology franchise remain on track at Exelixis with the news that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is recommending that Cometriq cabozantinib be available to treat metastatic medullary thyroid cancer (MTC) in the European Union. If approved by the European Commission Cometriq will be commercialized in the EU by Swedish Orphan Biovitrum (Sobi).